NovoCure Limited (NVCR) stock surged 17 percent on Thursday after it announced that FDA has approved its Premarket Approval or PMA application based on the LUNAR, which mentioned the usage of TTFields therapy for the treatment of non-small cell lung cancer or NSCLC.